{
    "organizations": [],
    "uuid": "b514df0f8136c1243e30d62b5c7ebd6590f9d395",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aequus-receives-positive-fda-regul/brief-aequus-receives-positive-fda-regulatory-guidance-for-anti-nausea-patch-idUSFWN1SA0TU",
    "ord_in_thread": 0,
    "title": "Aequus Receives Positive FDA Regulatory Guidance For Anti-Nausea Patch",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - Aequus Pharmaceuticals Inc:\n* AEQUUS RECEIVES POSITIVE FDA REGULATORY GUIDANCE FOR ANTI-NAUSEA PATCH\n* AEQUUS PHARMACEUTICALS INC - FDA HAS CONFIRMED THAT AN ABBREVIATED 505(B)(2) REGULATORY PATHWAY WOULD BE APPROPRIATE FOR SUBMISSION OF AQS1303\n* AEQUUS PHARMACEUTICALS - FDA INDICATED BIOEQUIVALENCE STUDY TO BRIDGE ORAL DICLEGIS(®) SAFETY AND EFFICACY DATA WITH AQS1303 IS LIKELY ACCEPTABLE\n* AEQUUS PHARMACEUTICALS INC - FDA HAS AGREED WITH AEQUUS’ PROPOSED CLINICAL PLAN FOR AQS1303\n* AEQUUS PHARMACEUTICALS-RECEIVED POSITIVE FEEDBACK FROM U.S. FDA ON ITS PRE-IND SUBMISSION FOR CO’S LONG-ACTING ANTI-NAUSEA TRANSDERMAL PATCH, AQS1303 Source text for Eikon:\nOur ",
    "published": "2018-05-03T20:49:00.000+03:00",
    "crawled": "2018-05-04T17:09:54.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aequus",
        "pharmaceutical",
        "inc",
        "aequus",
        "receives",
        "positive",
        "fda",
        "regulatory",
        "guidance",
        "patch",
        "aequus",
        "pharmaceutical",
        "inc",
        "fda",
        "confirmed",
        "abbreviated",
        "b",
        "regulatory",
        "pathway",
        "would",
        "appropriate",
        "submission",
        "aqs1303",
        "aequus",
        "pharmaceutical",
        "fda",
        "indicated",
        "bioequivalence",
        "study",
        "bridge",
        "oral",
        "diclegis",
        "safety",
        "efficacy",
        "data",
        "aqs1303",
        "likely",
        "acceptable",
        "aequus",
        "pharmaceutical",
        "inc",
        "fda",
        "agreed",
        "aequus",
        "proposed",
        "clinical",
        "plan",
        "aqs1303",
        "aequus",
        "positive",
        "feedback",
        "fda",
        "submission",
        "co",
        "transdermal",
        "patch",
        "aqs1303",
        "source",
        "text",
        "eikon"
    ]
}